Novel use of L-DOPA in the treatment of anorexia and asthenia associated with cancer

Lozano, Ramon Herreros
November 2002
Palliative Medicine;Nov2002, Vol. 16 Issue 6, p548
Academic Journal
No abstract available.


Related Articles

  • Novel use of L-DOPA in the treatment of anorexia and asthenia associated with cancer. Lozano, Ramon Herreros; Jofre, Irene Serrat // Palliative Medicine;Oct2002, Vol. 16 Issue 6, p548 

    Focuses on the novel use of L-DOPA in the treatment of anorexia and asthenia associated with cancer. Alleged improvement in anorexia patients.

  • Controlled Clinical Trial of L--Dopa and Nafoxidine in Advanced Breast Cancer: An E.O.R.T.C. Study. Engelsman, E.; Heuson, J.C.; der Wijst, J. Blonk-Van; Drochmans, A.; Maass, H.; Cheix, F.; Sobrinho, L.G.; Nowakowski, H. // British Medical Journal;6/28/1975, Vol. 2 Issue 5973, p714 

    Presents a clinical trial of L-Dopa and Nafoxidine in postmenopausal women with advanced breast cancer. Therapeutic use of L-Dopa in the treatment of patients with breast cancer; Failure of L-Dopa to achieve objective remissions in patients; Ineffectiveness of L-Dopa in advanced breast cancer...

  • Effect of Sipjeondaebo-Tang on Cancer-Induced Anorexia and Cachexia in CT-26 Tumor-Bearing Mice. Youn Kyung Choi; Ki Yong Jung; Sang-Mi Woo; Yee Jin Yun; Chan-Yong Jun; Jong Hyeong Park; Yong Cheol Shin; Sung-Gook Cho; Seong-Gyu Ko // Mediators of Inflammation;2014, Vol. 2014, p1 

    Cancer-associated anorexia and cachexia are amultifactorial condition described by a loss of bodyweight andmuscle with anorexia, asthenia, and anemia. Moreover, they correlate with a high mortality rate, poor response to chemotherapy, poor performance status, and poor quality of life. Cancer...

  • Deuterium-substituted l-DOPA displays increased behavioral potency and dopamine output in an animal model of Parkinson's disease: comparison with the effects produced by l-DOPA and an MAO-B inhibitor. Malmlöf, Torun; Feltmann, Kristin; Konradsson-Geuken, Åsa; Schneider, Frank; Alken, Rudolf-Giesbert; Svensson, Torgny; Schilström, Björn // Journal of Neural Transmission;Feb2015, Vol. 122 Issue 2, p259 

    The most effective treatment of Parkinson's disease (PD) l-DOPA is associated with major side effects, in particular l-DOPA-induced dyskinesia, which motivates development of new treatment strategies. We have previously shown that chronic treatment with a substantially lower dose of...

  • Etirinotecan pegol.  // Reactions Weekly;12/19/2015, Vol. 1582 Issue 1, p197 

    The article describes the case of diarrhoea, alopecia, asthenia and anorexia that developed in a 49-year-old woman during treatment with etirinotecan pegol.

  • Management of L-dopa overdose in the competitive inhibition state. Hinz, Marty; Stein, Alvin; Cole, Ted // Drug, Healthcare & Patient Safety;2014, Vol. 6, p93 

    The amino acid L-3,4-dihydroxyphenylalanine (L-dopa) is prescribed for conditions where increased central and/or peripheral dopamine synthesis is desired. Its administration can establish dopamine concentrations higher than can be achieved from an optimal diet. Specific indications include...

  • Overview of the tolerability of gefitinib (IRESSA) monotherapy : clinical experience in non-small-cell lung cancer. Forsythe, Beverley; Faulkner, Karen // Drug Safety;2004, Vol. 27 Issue 14, p1081 

    Cytotoxic chemotherapy treatment options for patients with non-small-cell lung cancer (NSCLC) have limited efficacy and are often associated with significant toxicity. Therefore, there is an unmet need for novel drugs that are not only effective in treating this disease but are also well...

  • Management of specific symptom complexes in patients receiving palliative care. Bruera, Eduardo; Neumann, Catherine M. // CMAJ: Canadian Medical Association Journal;06/30/98, Vol. 158 Issue 13, p1717 

    Discusses the Canadian management of the most common symptoms of terminal cancer. The receiving of palliative care; Seven different cases of cancer patients; Cancer pain; The use of opioid agonists and adjuvant drugs; Cachexia-anorexia syndrome; The use of corticosteroids and progestational...

  • Cyproterone/flutamide.  // Reactions Weekly;11/10/2007, Issue 1177, p11 

    The article describes the case of a 78-year-old man who developed liver injury episodes following consecutive flutamide and cyproterone treatment for advanced prostate cancer. Some of the symptoms experienced by the patient were asthenia, anorexia, choluria and jaundice. His abdominal...

  • Panitumumab.  // Reactions Weekly;Oct2015, Vol. 1572 Issue 1, p160 

    The article presents a case study of a patient who developed asthenia after treatment with panitumumab for metastatic colorectal cancer.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics